Polyamide Compound for Peripheral Analgesia via Reduced Brain Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current κ-opioid receptor agonists face challenges such as systemic side effects, poor anesthetic effect at allowed doses, and development issues due to high brain penetration and toxicity, along with addiction potential and tolerance development.
Innovation Solution
A novel polyamide compound with high κ-opioid receptor agonistic activity, low brain penetration, and improved physicochemical and pharmacokinetic properties, including high selectivity for κ-opioid receptors over μ and δ-opioid receptors, is developed, featuring a specific structure with hydrophilic groups that reduce lipid-water partition coefficients and enhance bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If first-generation κ-opioid receptor agonists (spiradoline, enadoline) are administered orally, then they can enter the brain and produce analgesic effect, but they cause central nervous system side effects such as dysphoria and hallucination
Solution Approach 1:
The patent modifies the chemical structure of κ-opioid receptor agonists by introducing specific polyamide compounds with controlled hydrophilic groups, changing the lipid-water partition coefficient parameter to achieve reduced brain penetration while maintaining peripheral analgesic activity
Solution Approach 2:
The invention creates compounds with differentiated properties for different body regions - high hydrophilicity for peripheral selectivity and low brain penetration, while maintaining adequate lipophilicity for local tissue penetration at the administration site
2Object-affected harmful factors
If second-generation κ-opioid receptor agonists (asimadoline) are used to increase peripheral selectivity, then central side effects are reduced, but anesthetic effect becomes insufficient at allowed doses
Solution Approach 1:
The patent optimizes the balance between hydrophilicity and lipophilicity parameters by controlling the number and position of hydroxyl groups and alkyl chains, achieving compounds that maintain adequate tissue penetration while selectively targeting peripheral κ-opioid receptors
Solution Approach 2:
The invention combines multiple functional groups (amide bonds, hydroxyl groups, alkyl chains) in specific configurations to create composite molecular structures that simultaneously achieve peripheral selectivity and sufficient analgesic efficacy
3Reliability
If κ-opioid receptor agonists are administered systemically to achieve adequate analgesic effect, then pain relief is improved, but respiratory depression and addiction potential increase
Solution Approach 1:
The patent extracts the analgesic function from the central nervous system by designing compounds that selectively target peripheral κ-opioid receptors, separating the therapeutic effect from the harmful central side effects
Solution Approach 2:
The invention uses peripheral κ-opioid receptors as intermediaries to produce analgesic effects without requiring central nervous system activation, thereby avoiding respiratory depression and addiction associated with μ-opioid receptor agonists
4Reliability
If the lipid-water partition coefficient is increased to improve tissue penetration, then analgesic efficacy is enhanced, but brain penetration increases causing sedation and hallucination
Solution Approach 1:
The patent precisely controls the lipid-water partition coefficient by adjusting the hydrocarbon chain length and hydroxyl group content, achieving an optimal balance that allows sufficient tissue penetration while preventing excessive brain accumulation
Data Source
AI summary
The invention relates to a polyamide compound and a use thereof. Specifically, the invention relates to a type of polyamide compound (which preferably comprise one or more amide bonds formed by condensation of same or different L-amino acids or D-amino acids), or stereoisomers, crystalline polymorphs, solvates, metabolites, prodrugs or pharmaceutically acceptable salts or esters thereof, or pharmaceutical compositions thereof, as well as a method for preparing the polyamide compound and a use thereof in the prevention or treatment of diseases associated with κ-opioid receptor. The polyamide compound of the invention has excellent κ-opioid receptor agonistic activity and hydrophilicity, thus having a lesser ability of penetrating the blood-brain barrier and a lower capacity for entering the brain. The compound of the invention has higher selectivity for a κ-opioid receptor, lower addictiveness, improved pharmacokinetic properties, and improved safety (lower toxicity and/or fewer side effects), good patient compliance, and/or lesser propensity for developing tolerance, among other excellent medicinal properties.